Verona Pharma Plc’s Corporate Rating Reaffirmed at N+1 Singer (VRP)
Shares of Verona Pharma Plc (LON:VRP) traded up 5.78% during mid-day trading on Thursday, hitting GBX 1.19. The stock had a trading volume of 102,055 shares. Verona Pharma Plc has a one year low of GBX 1.00 and a one year high of GBX 5.97. The stock has a 50-day moving average of GBX 1.24 and a 200-day moving average of GBX 2.33.
VRP has been the subject of a number of other recent research reports. Analysts at Beaufort Securities downgraded shares of Verona Pharma Plc to a “sell” rating in a research note on Tuesday, June 24th. Analysts at WH Ireland reiterated a “buy” rating on shares of Verona Pharma Plc in a research note on Monday, June 23rd.
Verona Pharma plc is a biotechnology company. The Company is engaged in research, discovery and development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (LON:VRP), asthma, allergic rhinitis (hay fever), and cough.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.